{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:45:50Z","timestamp":1787028350354,"version":"build-2736575974"},"reference-count":41,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>High-density lipoproteins (HDL) play an important role in the prevention of atherosclerosis. The aim of the study was to assess the relationship between serum HDL-C concentration and proinflammatory\/prothrombic activation in coronary artery disease (CAD) patients. The study group included 27 acute myocardial infarction (AMI) patients and 30 stable angina pectoris (SA) patients. The control group consisted of 23 people without cardiac symptoms. In the AMI and SA groups, a lower HDL-C and a higher LDL-C\/HDL-C index were observed. The SA patients had lower total cholesterol, LDL-C, sE-selectin ligand, as well as higher triglycerides and CD40 concentration in comparison with both the control and AMI groups. A higher von Willebrand Factor and intercellular adhesion molecule-1 were found in both study groups. Low HDL-C concentration in the CAD patients may intensify pro-inflammatory endothelial activation and prothrombotic processes. A low concentration of HDL-C and a high value of the LDL-C\/HDL-C index seem to be better indices of atherogenic processes than the LDL-C concentration alone.<\/jats:p>","DOI":"10.3390\/ijerph19148637","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T22:57:06Z","timestamp":1658098626000},"page":"8637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Low High-Density Lipoprotein Level on Endothelial Activation and Prothrombotic Processes in Coronary Artery Disease\u2014A Pilot Study"],"prefix":"10.3390","volume":"19","author":[{"given":"Magdalena","family":"Lampka","sequence":"first","affiliation":[{"name":"Department of Pathobiochemistry and Clinical Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-451X","authenticated-orcid":false,"given":"Dorota","family":"Olszewska-S\u0142onina","sequence":"additional","affiliation":[{"name":"Department of Pathobiochemistry and Clinical Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-5604","authenticated-orcid":false,"given":"Iga","family":"Ho\u0142y\u0144ska-Iwan","sequence":"additional","affiliation":[{"name":"Department of Pathobiochemistry and Clinical Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Gr\u0105bczewska","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Internal Diseases, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0440-2563","authenticated-orcid":false,"given":"Karolina","family":"Obo\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Internal Diseases, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cwynar","sequence":"additional","affiliation":[{"name":"Department of Pathobiochemistry and Clinical Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"St\u0119powska","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-3882","authenticated-orcid":false,"given":"Karolina","family":"Szewczyk-Golec","sequence":"additional","affiliation":[{"name":"Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1253\/circj.CJ-13-1025","article-title":"High-density lipoproteins\u2014Multifunctional but vulnerable protections from atherosclerosis","volume":"77","author":"Annema","year":"2013","journal-title":"Circ. J."},{"key":"ref_2","first-page":"274629","article-title":"Friends turns foe: Transformation of anti-inflammatory HDL to proinflammatory HDL during acute phase response","volume":"2011","author":"Rao","year":"2011","journal-title":"Cholesterol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1440-1681.2010.05377.x","article-title":"High-density lipoproteins, platelets and the pathogenesis of atherosclerosis","volume":"37","author":"Nofer","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"212525","DOI":"10.7573\/dic.212525","article-title":"High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease","volume":"7","author":"Kosmas","year":"2018","journal-title":"Drugs Context"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5551\/jat.12823","article-title":"Apolipoprotein A-1 inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages","volume":"19","author":"Yin","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2005.12.030","article-title":"Circulating markers of endothelial function in cardiovascular disease","volume":"368","author":"Constans","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2011.10.009","article-title":"Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina","volume":"413","author":"Tretjakovs","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fphys.2015.00234","article-title":"Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome?","volume":"6","author":"Moreira","year":"2015","journal-title":"Front. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32508","DOI":"10.1155\/MI\/2006\/32508","article-title":"Soluble CD40 ligand levels in otherwise healthy subject with impaired fasting glucose","volume":"5","author":"Tasci","year":"2006","journal-title":"Mediat. Inflamm."},{"key":"ref_10","first-page":"1769","article-title":"ESC Committee for Practice Guidelines (CPG) 2008\u20132010 and 2010\u20132012 Committees, ESC\/EAS guidelines for the management for dyslipidaemias, The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), European Association for Cardiovascular Prevention & Rehabilitation","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/1755-5922.12072","article-title":"Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid\/laropiprant on oxidative stress markers in patients with mixed dyslipidemia","volume":"32","author":"Kei","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5551\/jat.3848","article-title":"Switching to aggressive statin improves vascular endothelial functions in patients with stable coronary artery disease","volume":"17","author":"Hoshiga","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/ki.2008.514","article-title":"Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: A substudy of ACTFAST","volume":"74","author":"Farsang","year":"2008","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOL.0000000000000382","article-title":"Inflammation, Remodeling and Other Factors Affecting HDL Cholesterol Efflux","volume":"28","author":"Ronsein","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cca.2014.09.024","article-title":"HDL functionality and crystal-based sterile inflammation in atherosclerosis","volume":"439","author":"Eren","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5551\/jat.26765","article-title":"Men with lower HDL cholesterol levels have significant increment of soluble CD40 ligand and high-sensitivity CRP levels following the cessation of long-term clopidogrel therapy","volume":"22","author":"Obradovic","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/ncomms4292","article-title":"HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells","volume":"5","author":"Tabet","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trsl.2016.02.008","article-title":"Dysfunctional high-density lipoproteins in coronary heart disease: Implications for diagnostics and therapy","volume":"173","author":"Annema","year":"2016","journal-title":"Transl. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11883-010-0091-x","article-title":"Dysfunctional high-density lipoprotein and atherosclerosis","volume":"12","author":"Ragbir","year":"2010","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacl.2016.08.003","article-title":"HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels","volume":"10","author":"Annema","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0026-0495(03)00157-4","article-title":"Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipidemia","volume":"52","author":"Lupattelli","year":"2003","journal-title":"Metabolism"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/hq0402.105901","article-title":"Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol","volume":"22","author":"Calabresi","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1536\/ihj.46.593","article-title":"Lack of association between low HDL-cholesterol and elevated circulating cellular adhesion molecules in normolipidemic CAD patients and healthy subjects","volume":"46","author":"Kalimanovska","year":"2005","journal-title":"Int. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2004-03-1106","article-title":"Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"Von Willebrand factor in cardiovascular disease, Focus on acute coronary syndrome","volume":"117","author":"Spiel","year":"2008","journal-title":"Circ. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5620314","DOI":"10.1155\/2017\/5620314","article-title":"The role of von Willebrand Factor in vascular inflammation: From pathogenesis to targeted therapy","volume":"2017","author":"Gragnano","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0009-8981(02)00014-1","article-title":"Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome","volume":"319","author":"Peng","year":"2002","journal-title":"Clin. Chim. Acta"},{"key":"ref_29","first-page":"92","article-title":"Soluble CD40 ligand, soluble P-selectin, and von Willebrand factor level in subjects with prediabetes: The impact of metabolic syndrome","volume":"45","author":"Genc","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.atherosclerosis.2006.12.008","article-title":"Atherosclerosis risk factors in children of parents with metabolic syndrome","volume":"194","author":"Akinci","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoproteins cholesterol, non-high density lipoproteins cholesterol, apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e003665","DOI":"10.1161\/JAHA.116.003665","article-title":"Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol","volume":"5","author":"Sniderman","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.clinbiochem.2009.05.004","article-title":"Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis","volume":"42","author":"Vaverkova","year":"2009","journal-title":"Clin. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1874091X01206010078","article-title":"High density lipoprotein and it\u2019s dysfunction","volume":"6","author":"Eren","year":"2012","journal-title":"Open Biochem. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cjca.2016.09.012","article-title":"High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management","volume":"33","author":"Choi","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"891403","DOI":"10.1155\/2013\/891403","article-title":"HDL, Atherosclerosis, and emerging therapies","volume":"2013","author":"Hafiane","year":"2013","journal-title":"Cholesterol"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Halcox, J.P., Banegas, J.R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K.M., and Borghi, C. (2017). Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-017-0591-5"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/cvr\/cvaa085","article-title":"Endothelial function in cardiovascular medicine: A consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis","volume":"117","author":"Alexander","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Severino, P., D\u2019Amato, A., Prosperi, S., Magnocavallo, M., Mariani, M.V., Netti, L., Birtolo, L.B., De Orchi, P., Chimenti, C., and Maestrini, V. (2021). Potential Role of eNOS Genetic Variants in Ischemic Heart Disease Susceptibility and Clinical Presentation. About J. Cardiovasc. Dev. Dis., 8.","DOI":"10.3390\/jcdd8090116"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamacardio.2016.0218","article-title":"Drugs for primary prevention of atherosclerotic cardiovascular disease: An overview of systematic reviews","volume":"1","author":"Karmali","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/14779072.6.1.95","article-title":"The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease","volume":"6","author":"Hennekens","year":"2008","journal-title":"Expert Rev. Cardiovasc. Ther."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/14\/8637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:51:26Z","timestamp":1760140286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/14\/8637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":41,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijerph19148637"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19148637","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}